Cargando…
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
Allogeneic transplant (alloHCT) and chimeric antigen receptor modified (CAR)-T cell therapy are potentially cuarative options of diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous (auto)HCT. Although the Center for International Blood and Marrow Transplant Research (CIBMTR) prognost...
Autores principales: | Hamadani, Mehdi, Gopal, Ajay K., Pasquini, Marcelo, Kim, Soyoung, Qiu, Xianmiao, Ahmed, Sairah, Lazaryan, Aleksandr, Bhatt, Vijaya Raj, Daly, Andrew, Lulla, Premal, Ciurea, Stefan, Gauthier, Jordan, Agrawal, Vaibhav, Grover, Natalie S., Lekakis, Lazaros, Modi, Dipenkumar, Dahi, Parastoo B., Herr, Megan M., Johnson, P. Connor, Hashmi, Hamza, Hematti, Peiman, Locke, Frederick L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791562/ https://www.ncbi.nlm.nih.gov/pubmed/34673903 http://dx.doi.org/10.1182/bloodadvances.2021005788 |
Ejemplares similares
-
COVID-specific T's may offset therapeutically endangered B's
por: Hill, LaQuisa C., et al.
Publicado: (2022) -
The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021) -
A germinal center–associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
por: Miyawaki, Kohta, et al.
Publicado: (2022) -
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022) -
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
por: Merryman, Reid W., et al.
Publicado: (2022)